Allogeneic CAR T Cells: Complex Cellular Therapy Designs Test the Limits of Our Preclinical Models.

IF 8.1 1区医学 Q1 IMMUNOLOGY

Cancer immunology research Pub Date : 2024-04-02 DOI:10.1158/2326-6066.CIR-24-0204

Paolo F Caimi, Jan Joseph Melenhorst

引用次数: 0

Abstract

All chimeric antigen receptor (CAR) T-cell products currently approved by the FDA are autologous, which poses several challenges for widespread use. In this issue, Degagné and colleagues present their preclinical research on creating off-the-shelf CAR T cells for multiple myeloma. They utilized the CRISPR/Cas12a genome editing platform and gene knock-in techniques to eliminate alloreactivity and decrease susceptibility to natural killer (NK)-cell elimination. This work has led to an ongoing phase I trial of off-the-shelf CAR T cells for multiple myeloma treatment. See related article by Degagné et al., p. 462 (2).

查看原文本刊更多论文

异体 CAR T 细胞：复杂的细胞疗法设计考验我们临床前模型的极限。

目前美国食品及药物管理局批准的所有嵌合抗原受体（CAR）T细胞产品都是自体细胞，这给广泛应用带来了一些挑战。在本期杂志中，Degagné及其同事介绍了他们针对多发性骨髓瘤创建现成CAR T细胞的临床前研究。他们利用CRISPR/Cas12a基因组编辑平台和基因敲入技术消除异体活性，降低对自然杀伤（NK）细胞的易感性。这项工作促使现成的 CAR T 细胞用于多发性骨髓瘤治疗的 I 期试验正在进行中。参见 Degagné 等人的相关文章，第 462 页（2）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer immunology research ONCOLOGY-IMMUNOLOGY

CiteScore

15.60

自引率

1.00%

发文量

260

期刊介绍： Cancer Immunology Research publishes exceptional original articles showcasing significant breakthroughs across the spectrum of cancer immunology. From fundamental inquiries into host-tumor interactions to developmental therapeutics, early translational studies, and comprehensive analyses of late-stage clinical trials, the journal provides a comprehensive view of the discipline. In addition to original research, the journal features reviews and opinion pieces of broad significance, fostering cross-disciplinary collaboration within the cancer research community. Serving as a premier resource for immunology knowledge in cancer research, the journal drives deeper insights into the host-tumor relationship, potent cancer treatments, and enhanced clinical outcomes. Key areas of interest include endogenous antitumor immunity, tumor-promoting inflammation, cancer antigens, vaccines, antibodies, cellular therapy, cytokines, immune regulation, immune suppression, immunomodulatory effects of cancer treatment, emerging technologies, and insightful clinical investigations with immunological implications.

文献相关原料

公司名称	产品信息	采购帮参考价格